Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Feb;93(2):E45-E47.
doi: 10.1002/ajh.24965. Epub 2017 Nov 27.

Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis

Marina Jerebtsova  1 , Santosh L Saraf  2 , Xionghao Lin  3 , Gillian Lee  3 , Elena Afia Adjei  3   4 , Namita Kumari  3 , Nowah Afangbedji  3 , Rasha Raslan  2 , Charlee McLean  3 , Victor R Gordeuk  2 , Sergei Nekhai  1   3   5
Affiliations

Identification of ceruloplasmin as a biomarker of chronic kidney disease in urine of sickle cell disease patients by proteomic analysis

Marina Jerebtsova et al. Am J Hematol. 2018 Feb.
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Ceruloplasmin (CP) in urine correlates with development of CKD in SCD patients
(A) CP is identified by proteomic analysis of urine. Urine samples with and without hemoglobinuria (N=3 each) were selected from 20 SCD patients without proteinuria and albuminuria. SCD samples without hemoglobinuria were defined as SCD controls. Urine proteins were concentrated and desalted by centrifugation, trypsinized and analyzed by mass spectrometry. Proteins were identified by Proteome Discoverer 1.4 and quantified by SIEVE 2.1. Average intensities shown were derived from integration of ion elution profiles. (B) CP is present in urine samples. Urine samples from SCD without and with hemoglobinuria were separated by SDS PAGE and analyzed by Western blotting with antibodies against CP. Arrow indicates a position of CP. (C–D) Urine ceruloplasmin and hemoglobin correlated with stages of CKD. Correlation analysis was conducted for (C) ceruloplasmin (CP) and (D) hemoglobin (Hgb) to creatinine (CRE) ratios with stages of CKD in 34 SCD patients. Pearson correlation analysis was performed using GraphPad software in 34 SCD patients with different stages of CKD (0–5). (E) Correlation analysis of urinary hemoglobin (Hgb) and CP. CP/CRE and Hgb/CRE ratios are shown. Pearson correlation analysis was performed using GraphPad software. (F) Specificity and sensitivity of urinary ceruloplasminin SCD patients. ROC analysis of urinary CP/CRE and Hgb/CRE is shown for urine samples from SCD patients with stage 0 CKD versus stage 1–5 CKD. The analysis was performed using GraphPad software.
See this image and copyright information in PMC

References

    1. Airy M, Eknoyan G. The kidney in sickle hemoglobinopathies. Clinical nephrology. 2017;87(2017):55–68. - PubMed
    1. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clinical practice. 2012;120:c179–184. - PubMed
    1. Drawz P, Ayyappan S, Nouraie M, et al. Kidney Disease among Patients with Sickle Cell Disease, Hemoglobin SS and SC. Clinical journal of the American Society of Nephrology : CJASN. 2016;11:207–215. - PMC - PubMed
    1. Hatch FE, Culbertson JW, Diggs LW. Nature of the renal concentrating defect in sickle cell disease. The Journal of clinical investigation. 1967;46:336–345. - PMC - PubMed
    1. Saraf SL, Zhang X, Kanias T, et al. Haemoglobinuria is associated with chronic kidney disease and its progression in patients with sickle cell anaemia. British journal of haematology. 2014;164:729–739. - PMC - PubMed

Publication types